FCA authorised · FRN 724952 0117 325 0027Quote & buy →
Aipedia: Aesthetics clinics
In 2026 no rule addresses AI in aesthetics directly, so GMC cosmetic guidance, CAP advertising rules, data protection law and the professional codes govern how clinics use it. Practitioners who assume an AI gap is a rules gap risk regulatory action and uninsured claims.
Part of: AI in aesthetics clinics
In short
There is no AI-specific guidance for aesthetics from DHSC, the JCCP, the ASA and CAP or the professional regulators. The rules that apply are existing ones: GMC cosmetic guidance paras 11 (physical examination before prescribing injectables), 16 (personal consent) and 47 to 49 (responsible marketing); CAP rules 12.12 (no POM advertising) and 3.47 to 3.50 (genuine before-and-after images); and the automated decision safeguards in the Data (Use and Access) Act 2025. Section 180 licensing and the October 2026 DHSC consultation will reshape who can treat, while the PSA joint AI statement binds registrant prescribers in principle.
Aesthetics is regulated by who you are, not what you do. Doctors, nurses, dentists and pharmacists answer to their own statutory regulators; non-healthcare practitioners in England have no statutory regulator at all. Advertising is a separate regime run by the ASA and CAP, and medicines and devices sit with the MHRA. None of these bodies has published guidance mentioning AI in aesthetics. The practical consequence is that every AI tool is judged against the duty it touches: prescribing, consent, advertising, records or data.
| Source | Date | Status | Key point for AI use |
|---|---|---|---|
| GMC cosmetic interventions guidance, para 11 | In force | Binding professional standard for doctors | Physical examination before prescribing injectable cosmetic medicines; no online or remote prescribing |
| GMC guidance, para 16 | In force | Binding for doctors | The practitioner performing the procedure seeks consent personally |
| GMC guidance, paras 47 to 49 | In force | Binding for doctors | Marketing follows CAP, is factual and responsible, does not exploit vulnerability |
| CAP rule 12.12 and CAP advice | Advice 29 Oct 2025 | Code binding on advertisers; advice is guidance | Almost any public Botox reference, including hashtags, is likely a POM ad |
| CAP rules 3.47 to 3.50 and CAP advice | Advice 5 June 2025 | Code binding; advice is guidance | Before-and-after images need signed, dated proof they are genuine and unmanipulated |
| ASA ruling, Glow Up LLC | 2 Sept 2026 | Upheld ruling | AI transformations not shown to be genuine or typical; ads irresponsible |
| Health and Care Act 2022 s180 | In force 1 July 2022 | Enabling power; no regulations yet | Licensing of practitioners and premises |
| DHSC high-risk procedures consultation | 21 Oct 2026 to 13 Jan 2027 | Proposal | Restricts certain high-risk treatments, including some laser procedures, to healthcare professionals |
| PSA joint statement of intent on AI | 17 Sept 2026 | Statement of principles | Signed by the GMC, NMC, GDC, GPhC and others |
The GMC cosmetic interventions FAQs set out the paragraphs that matter most. Para 11 says doctors must physically examine patients before prescribing injectable cosmetic medicines such as Botox, and must not prescribe them by telephone, video link, online or at the request of others for patients they have not examined. An AI questionnaire cannot satisfy this. Para 16 places the consent discussion on the practitioner who will perform the procedure, so an AI-generated form or a chatbot cannot take it over. Paras 24 to 26 add that patients need time and information to decide and can change their mind.
Paras 47 to 49 require marketing to follow the CAP Codes, to be factual and verifiable, and to be responsible. It must not minimise or trivialise risk, must not claim interventions are risk free and must not exploit vulnerability. AI-written captions and AI-generated images fall squarely within these duties. For nurses, NMC Code 20.10 requires responsible use of digital communication; HCPC standard 9.3 and GMC Domain 4 require communications to be accurate and not misleading.
CAP rule 12.12 prohibits advertising prescription-only medicines to the public. The CAP advice on botulinum toxin (29 October 2025) says almost any reference to Botox in non-broadcast or social media marketing, including hashtags, is likely to be an implied POM ad. The ASA has upheld complaints on this point in a number of rulings since 2015.
Rules 3.47 to 3.50 treat before-and-after photos like testimonials. The CAP advice on before and after photos (5 June 2025) says advertisers need signed, dated proof that images are genuine and unmanipulated, and that retouching affecting apparent results can mislead. The Glow Up ruling applied the misleading advertising rules (CAP 3.1, 3.7 and 3.11) to AI-generated transformations and the social responsibility rules (CAP 1.3 and 4.9) to body-image pressure on young people. It is the closest precedent for AI appearance claims.
Section 180 of the Health and Care Act 2022 allows licensing of individuals and premises offering specified cosmetic procedures in England. No licensing regulations have been made. The DHSC consultation, open from 21 October 2026 to 13 January 2027, would restrict certain high-risk treatments, including some laser procedures, to doctors, dentists, independent prescribing nurses, midwives and pharmacists, treat liquid BBL as surgery for doctors only, and ban specified treatments for under-18s. The legal route is a draft amendment to the regulated activities regulations, with breaches a criminal offence enforced by the CQC. DHSC says parliamentary process is planned for spring 2027. A separate licensing scheme for toxins and fillers is committed to, without a date. Neither the consultation page nor the DHSC announcement mentions insurance or AI.
On 17 September 2026 the PSA and health and social care regulators issued a joint statement of intent on AI principles, signed by the GMC, NMC, GDC and GPhC among others. It is a statement of intent rather than a new code, but it signals that registrant prescribers and injectors will be expected to use AI within their existing professional duties. It does not reach non-healthcare practitioners.
Indemnity is compulsory for registrants under their statutes, and NHS indemnity does not cover private cosmetic work. One medical defence organisation supports AI use only where a human remains the decision maker, excluding autonomous systems and software defects. Commercial aesthetic policies differ, so cover usually depends on the wording and on disclosing AI tools. See aesthetic clinic insurance, what to document about AI use, does aesthetic insurance cover AI, AI questionnaires and remote prescribing, AI images in ads and the aesthetics AI hub.
Not specifically. Its cosmetic interventions guidance does not mention AI, but paras 11, 16 and 47 to 49 apply to any AI tool used for prescribing, consent or marketing. The GMC has also signed the PSA-led joint statement of intent on AI principles of 17 September 2026.
No. GMC para 11 requires a physical examination before prescribing injectable cosmetic medicines and rules out prescribing online, by telephone or video, or at the request of others for patients the doctor has not examined.
No. Neither the consultation page nor the DHSC announcement of 21 October 2026 mentions AI or insurance. It focuses on who may perform high-risk procedures, under-18s and CQC enforcement. Any AI or insurance conditions would have to come later, for example through licensing rules.
Tell us about your practice and the work you do. A broker will review how your current cover treats AI-assisted work, or arrange new cover. No fee for a quote. Or call 0117 325 0027.
Start an indemnity quote Request a callbackApex Insurance Brokers Limited is authorised and regulated by the Financial Conduct Authority. Registered in England and Wales, company number 07014570. This page is general information about how AI is used in the profession and how insurance may respond. It is not legal, regulatory or insurance advice on your circumstances, and it does not guarantee that cover will be available or on what terms.
